Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Brian Yang

Beijing-based Brian Yang is a senior writer in charge of overall China coverage within the APAC Pharma news team. A veteran journalist, he has written extensively on pharmaceutical R&D, regulatory affairs and market access for PharmAsia News. Brian’s intimate industry knowledge and in-depth analysis has won wide praise and helped secure exclusive interviews with top biopharma executives.
He has led a team of writers to provide industry-leading coverage on key issues such as multi-regional clinical trials, priority reviews and go-to-market strategies in a highly-dynamic and fast-changing market, with the on-the-ground coverage consistently ranked among the top-read in PharmAsia News.

Prior to joining Informa, Brian worked as a foreign affairs correspondent for two TV networks and web editor for an international radio station. Trilingual in Mandarin Chinese, English and Japanese, he obtained his BA degree from China and an MA degree from Japan.

Advertisement
Set Alert for Articles By Brian Yang

Latest From Brian Yang

Zai Lab Soars On Nasdaq Debut

Shanghai-based drug developer Zai Lab shares jumped on its first day of public trading, reflecting the strong interest in drug development in China.

Financing China

What's Driving The Uptick In Korea-China Biotech Deals

Bilateral ties between South Korea and China may have slumped to a new low, but that doesn’t seem to have deterred deals between firms in the two nations in the biotech space. Scrip takes a closer look at the deal-making flow and whether it is sustainable.

Commercial Deals

Asia Executives To Watch: Janssen, Biogen, Piramal

The coming of fall has brought with it a flurry of executive moves at Janssen China, Biogen, CANBridge and Piramal.

Appointments Research and Development Strategies

Can Patients Move The Rare Disease Treatment Needle In China?

Innovative orphan drug makers have so far largely shunned China but things could be changing. Chinese patient communities tell the Pink Sheet how they are increasingly taking it upon themselves to lobby regulators and persuade drug developers to include China in their clinical development consideration.

Rare Diseases China

Chinese API Maker Huahai Leaps Into IO Via Korean Startup

A frenzy for innovation has more Chinese companies armed with cash shopping for new assets. Huahai is the latest to jump onboard the increasingly competitive immuno-oncology field.

ImmunoOncology Research and Development Strategies

Asia Executives To Watch: Novartis China, GSK India, Cipla

Novartis’s former head of West China is moving to lead its global cardio-metabolic franchise, while GSK India and Cipla have made key personnel appointments on the manufacturing front.

Commercial Appointments
See All
Advertisement
UsernamePublicRestriction

Register